BCR and diffuse large B-cell lymphoma: Inhibition of BCR glycosylation by oligosaccharyltransferase-B reduces BCR clustering and internalization, thereby attenuating PI3K and NF-κB activation.173 This finding suggests that agents against the oligosaccharyltransferase-B glycosylation pathway may be useful for the treatment of DLBCL.